# PMV Pharma

Source: https://onco.cc/companies/pmv-pharma/  
OnCo record `pmv-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A listed US company developing a pill, rezatapopt, meant to repair one specific faulty form of the p53 protein, a natural brake on cancer. It is for solid tumours of any type that carry the TP53 Y220C mutation.

## Summary

PMV Pharmaceuticals develops small molecules intended to restore the function of mutant p53. Its lead candidate, rezatapopt (PC14586), is an oral p53 reactivator designed to stabilise the p53 Y220C mutant, which the company says accounts for 1.8% of p53 mutations and occurs in at least 30 tumour types. It is being evaluated tumour-agnostically in the pivotal Phase 2 portion of the PYNNACLE Phase 1/2 study (NCT04585750), alone and with pembrolizumab, and the FDA has granted it Fast Track designation. An investigator-initiated Phase 1b study with azacitidine in TP53 Y220C relapsed or refractory AML and MDS is run by M.D. Anderson Cancer Center (NCT06616636). The company was founded in 2013 by David Mack, Arnold Levine and Thomas Shenk, and trades on Nasdaq under PMVP according to its SEC filings.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: PMV Pharmaceuticals, Inc.; PMV Pharmaceuticals
- HQ: Princeton, NJ
- Type: biotech
- Website: https://www.pmvpharma.com/
- Ticker: NASDAQ: PMVP

## Notes

- Cancer ids left empty because rezatapopt is developed tumour-agnostically for TP53 Y220C; PYNNACLE lists many tumour types.
- NCT06616636 (rezatapopt with azacitidine) is sponsored by M.D. Anderson Cancer Center, not PMV, so it is not linked.

## Sources

- Official website: https://www.pmvpharma.com/
- Pipeline page: https://www.pmvpharma.com/pipeline/
- About and management: https://www.pmvpharma.com/about/
- ClinicalTrials.gov NCT04585750 (PYNNACLE): https://clinicaltrials.gov/study/NCT04585750
- SEC EDGAR filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001699382
- RA Capital portfolio entry: https://www.racap.com/portfolio/pmvpharma

## Connected records

- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [TP53](https://onco.cc/targets/tp53/)
- drugs: [Rezatapopt](https://onco.cc/drugs/rezatapopt/)
- trials: [A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)](https://onco.cc/trials/nct06616636/), [A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.](https://onco.cc/trials/nct07372625/), [The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)](https://onco.cc/trials/nct04585750/)
- companies: [RA Capital Management](https://onco.cc/companies/ra-capital/)

---
JSON: https://onco.cc/api/v1/entities/pmv-pharma.json